Zhang L - Search Results

1

Safety and feasibility of toripalimab plus lenvatinib with or without radiotherapy in advanced BTC.

Wang Y, Zhang N, Xue J, Zhu C, Wang Y, Zhang L, Yang X, Wang H, Wang S, Chao J, Yang X, Zhao H. Wang Y, et al. Among authors: zhang n, zhang l. Front Immunol. 2023 Jan 17;14:1084843. doi: 10.3389/fimmu.2023.1084843. eCollection 2023. Front Immunol. 2023. PMID: 36733485 Free PMC article.

2

Novel cellular therapies for hepatobiliary malignancies.

Xue JN, Wang YY, Wang YC, Zhang N, Zhang LH, Lu ZH, Zhao LJ, Zhao HT. Xue JN, et al. Hepatobiliary Pancreat Dis Int. 2022 Oct;21(5):450-454. doi: 10.1016/j.hbpd.2022.08.014. Epub 2022 Sep 6. Hepatobiliary Pancreat Dis Int. 2022. PMID: 36100543 Review.

3

High incidence combination of multiple primary malignant tumors of the digestive system.

Yang XB, Zhang LH, Xue JN, Wang YC, Yang X, Zhang N, Liu D, Wang YY, Xun ZY, Li YR, Sun HS, Zhao LJ, Zhao HT. Yang XB, et al. World J Gastroenterol. 2022 Nov 7;28(41):5982-5992. doi: 10.3748/wjg.v28.i41.5982. World J Gastroenterol. 2022. PMID: 36405110 Free PMC article.

4

Efficacy and safety of lenvatinib combined with PD-1/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer.

Zhu C, Xue J, Wang Y, Wang S, Zhang N, Wang Y, Zhang L, Yang X, Long J, Yang X, Sang X, Zhao H. Zhu C, et al. Among authors: zhang n, zhang l. Front Immunol. 2023 Jan 18;14:1109292. doi: 10.3389/fimmu.2023.1109292. eCollection 2023. Front Immunol. 2023. PMID: 36742297 Free PMC article.

5

Effectiveness and safety of radiotherapy plus programmed death-1 inhibitors and lenvatinib in patients with advanced biliary tract carcinoma: a real-world study.

Wang Y, Yang X, Wang Y, Xue J, Zhang N, Yang X, Cong N, Zhang J, Zhu C, Zhang L, Hou X, Zhao H. Wang Y, et al. Among authors: zhang n, zhang l, zhang j. Cancer Immunol Immunother. 2023 Jul;72(7):2197-2204. doi: 10.1007/s00262-023-03399-2. Epub 2023 Mar 1. Cancer Immunol Immunother. 2023. PMID: 36856834 Free PMC article.

6

Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma.

Wang YY, Yang X, Wang YC, Long JY, Sun HS, Li YR, Xun ZY, Zhang N, Xue JN, Ning C, Zhang JW, Zhu CP, Zhang LH, Yang XB, Zhao HT. Wang YY, et al. World J Gastroenterol. 2023 Mar 14;29(10):1614-1626. doi: 10.3748/wjg.v29.i10.1614. World J Gastroenterol. 2023. PMID: 36970591 Free PMC article.

7

Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study.

Zhu C, Li H, Yang X, Wang S, Wang Y, Zhang N, Wang Y, Xue J, Zhang L, Ning C, Yang X, Xun Z, Chao J, Long J, Sang X, Zhu Z, Zhao H. Zhu C, et al. Among authors: zhang n, zhang l. Cancer Immunol Immunother. 2023 Sep;72(9):2949-2960. doi: 10.1007/s00262-023-03466-8. Epub 2023 May 29. Cancer Immunol Immunother. 2023. PMID: 37247023 Free PMC article.

8

The efficacy and safety of bevacizumab as a salvage therapy for patients with advanced hepatocellular carcinoma targeting immune tolerance.

Zhang L, Xue J, Zhang N, Wang Y, Yang X, Wang S, Piao M, Liu K, Zhu C, Wang Y, Chao J, Ning C, Zhang X, Xun Z, Li Y, Sun H, Yang X, Zhao L, Zhao H. Zhang L, et al. Among authors: zhang n, zhang x. Am J Cancer Res. 2023 Aug 15;13(8):3582-3590. eCollection 2023. Am J Cancer Res. 2023. PMID: 37693157 Free PMC article.

9

Real-world cohort study of PD-1 blockade plus lenvatinib for advanced intrahepatic cholangiocarcinoma: effectiveness, safety, and biomarker analysis.

Chao J, Wang S, Wang H, Zhang N, Wang Y, Yang X, Zhu C, Ning C, Zhang X, Xue J, Zhang L, Piao M, Wang M, Yang X, Lu L, Zhao H. Chao J, et al. Among authors: zhang n, zhang l, zhang x. Cancer Immunol Immunother. 2023 Nov;72(11):3717-3726. doi: 10.1007/s00262-023-03523-2. Epub 2023 Oct 3. Cancer Immunol Immunother. 2023. PMID: 37787790 Free PMC article.

10

Efficacy and safety of subsequent radiotherapy in patients with advanced-stage hepatocellular carcinoma treated with immune checkpoint inhibitors.

Ning C, Jia J, Zhang X, Sun J, Wang Y, Xue J, Zhang L, Hou X, Yang X, Sang X, Duan X, Zhao H. Ning C, et al. Among authors: zhang l, zhang x. Hepatobiliary Surg Nutr. 2023 Dec 1;12(6):882-897. doi: 10.21037/hbsn-23-134. Epub 2023 May 31. Hepatobiliary Surg Nutr. 2023. PMID: 38115944 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

134,995 results

Search Page

Filters